Seòmar agus comataidhean

Brain and Central Nervous System cancer waiting times were part of the extending tumour site audit and were introduced into Cancer Waiting Times reporting for 2013 only. Since then, boards have not been required to submit these data. NHS boards may hold this data locally, PHS does not hold the data centrally.

The Scottish Government welcomes the survey undertaken by Cerebral Palsy Scotland in November 2021 and notes the findings.

Scottish Government officials recently met with Cerebral Palsy Scotland to further discuss the care and support available to people with this condition. We will continue to work with NHS, third sector partners and people with Cerebral Palsy to drive up standards of care and service development.

In December 2019, we published a Neurological Care and Support – National Framework for Action . We are investing £4.5 million of funding over five years to implement the Framework’s 17 commitments.

The aims include improving the provision of co-ordinated health and social care and support, developing sustainable workforce models and ensuring high standards of person-centred care for people with neurological conditions, such as Cerebral Palsy.

A search of the National Cancer Research Institute (NCRI) Cancer Research Database (CaRD) carried out by NCRI at the request of the Chief Scientist Office (CSO) showed the following allocation for CSO funded site-specific brain tumour research by Common Scientific Outline category

Category 1. Biology - total 4.1% /£22,275

Sub-category 1.5: Resources and Infrastructure - £22,275

Category 2. Aetiology

0

Category 3. Prevention

0

Category 4. Early Detection, Diagnosis and Prognosis - total 59.9% /£325,022

Sub-category 4.1: Technology Development and/or Marker Discovery - £67,767

Sub-category 4.2: Technology and/or Marker Evaluation - £134,305

Sub-category 4.4: Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis - £122,950

Category 5. Treatment - total 35.6% / £192,875

Sub-category 5.3: Systemic Therapies - Discovery and Development - £13,928

Sub-category 5.4: Systemic Therapies - Clinical Applications - £48,685

Sub-category 5.7: Resources and Infrastructure Related to Treatment and the Prevention of Recurrence £130,262

Category 6. Cancer Control, Survivorship, and Outcomes Research - total 0.4% / £2,195

Sub-category 6.2: Surveillance - £2,195

In the June 2021 round of the CSO Translational Clinical Studies Committee, the following research project was funded:

Developing representative models of the blood-tumour barrier to enhance drug development for Glioblastoma

Lead Investigator: Prof. Anthony Chalmers / Univeristy of Glasgow / £296,864 TCS2105.pdf (scot.nhs.uk)

This project will be categorised at the next update of the NCRI CaRD (scheduled Summer 2022)

The latest available statistics on NHS Waiting Times published up to 31 December 2021 can be accessed using the link below: https://www.publichealthscotland.scot/publications/nhs-waiting-times-stage-of-treatment/

The latest available statistics on NHS Waiting Times published up to 31 December 2021 can be accessed using the following link:

https://www.publichealthscotland.scot/publications/nhs-waiting-times-stage-of-treatment/

Public Health Scotland (PHS) notes that at 31 December 2021, 533 patients were waiting for treatment as an inpatient or daycase in NHS Grampian within the specialty of oral and maxillofacial surgery. 557 patients were waiting for a new outpatient appointment.

To improve waiting times across Scotland, the NHS Recovery Plan was published in August 2021. The 5 year plan will support an increase in inpatient daycase, and outpatient activity to address the backlogs of care, which will be supported by the implementation of sustainable improvements and new models of care.

The Scottish Government recognised the impact on businesses of measures to control Omicron including licensed clubs. As such they were eligible for hospitality funding including the Hospitality: December and January Business Support Top Up Fund and the Hospitality and Leisure: January Business Support Top Up Fund. These funds closed to applications on the 31 January 2022.

We have established a process for individuals who have received their coronavirus vaccinations outwith Scotland which allows for them to upload official proof of vaccination from an approved country to their Scottish Vaccination Record through NHS Inform . This will allow those who have been vaccinated within the UK or internationally to receive a combined fully vaccinated status to show for travel and domestic purposes.

National Record of Scotland (NRS) plan to publish the 1921 Scottish Census on the ScotlandsPeople Website ( ScotlandsPeople | Connecting Generations ) and in the ScotlandsPeople Centre as early as possible in the second half of 2022.

The Scottish Government is aware of the impact the necessary public health restrictions have had on businesses. We announced £375m of support for businesses impacted by measures introduced to control the spread of Omicron and this includes £19m for close contact businesses. This close contact fund is targeted at those who have been the most affected by the updated public health guidance introduced from 9 December 2021 to 24 January 2022, for example beauty services, hairdressers and wellness services. Driving instructors are not in scope at this stage.

The exact data requested is not held. The Cancer Waiting Times data does not report on average waits, however median waits are reported. The information below is for urological cancers and is provided both for 62-day and 31-day standard. The 62-day standard refers to ‘urgent’ referrals only and waiting times are from ‘urgent’ referral to the start of their first treatment for a newly diagnosed cancer. The 31-day standard is for ‘all’ referrals and waiting times are from the decision to treat to the start of their first treatment for a newly diagnosed cancer. Please note: the waiting times for 62-day and 31-day standards are not comparable as both standards refer to different cohorts of patients.

The Median length of wait between referral to first treatment (62-day standard) for urology cancers in 2017 was 49 days, 47 days in 2018, 45 days in 2019, 39 days in 2020 and 44 days in 2021.

The Median length of wait between decision to treat and first treatment (31-day standard) for urology cancers in 2017 was 12 days, 13 days in 2018, 11 days in 2019, 8 days in 2020 and 11 in 2021.

To note the median values for the year 2021 are based on the data that has already been published i.e. data for the months of January- September 2021.